Skip to main content
SpringerLink
Log in

Amyloid-Beta Immunization in Alzheimer's Disease Transgenic Mouse Models and Wildtype Mice

  • Published:
Neurochemical Research Aims and scope Submit manuscript

Abstract

Alzheimer's disease is the most prevalent form of dementia worldwide. Therapies are desperately needed to prevent and cure the disease. Mouse models of amyloid-β deposition [APP and PSAPP transgenic (tg) mice] have been useful in determining the role of amyloid-β (Aβ) in both the pathogenesis and cognitive changes in AD. In addition, they have allowed scientists to investigate potential AD therapies in living animals. Active and passive Aβ immunizations have been employed successfully in APP and PSAPP tg mice to lower cerebral Aβ levels and improve cognition. Optimization of immunization protocols and characterization of immune responses in wildtype mice have been reported. Based on the promising results of Aβ immunization studies in mice, a clinical trial was initiated for Aβ vaccination in humans with AD. Although no adverse effects were reported in the Phase I safety trials, about 5% of AD patients in the phase II clinical trial developed meningoencephalitis, ending the trial prematurely in March 2002. Studies in AD mouse models and wildtype mice may help elucidate the mechanism for these unwanted side effects and will be useful for testing newer, safer vaccines for future use in human clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Selkoe, D. J. 1999. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399:A23-A31.

    PubMed  Google Scholar 

  2. Games, D., Adams, D., Alessandrini, R., Barbour, R., Berthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., Guido, T., Hagopian, S., Johnson-Wood, K., Khan, K., Lee, M., Leibowitz, P., Lieberburg, I., Little, S., Masliah, E., McConlogue, L., Montoya-Zavala, M., Mucke, L., Paganini, L., Penniman, E., Power, M., Schenk, D., Seubert, P., Snyder, B., Soriano, F., Tan, H., Vitale, J., Wadsworth, S., Wolozin, B., and Zhao, J. 1995. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373:523–527.

    PubMed  Google Scholar 

  3. Hsiao, K., Chapman, P., Nilsen, S., Ekman, C., Harigaya, Y., Younkin, S., Yang, F., and Cole, G. 1996. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274:99–102.

    PubMed  Google Scholar 

  4. Mucke, L., Masliah, E., Yu, G.Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., and McConlogue, L. 2000. High-level neuronal expression of Aβ1–42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20:4050–4058.

    PubMed  Google Scholar 

  5. Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., Mount, H. T., Nixon, R. A., Mercken, M., Bergeron, C., Fraser, P. E., St George-Hyslop, P., and Westaway, D. 2000. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408:979–982.

    PubMed  Google Scholar 

  6. Borchelt, D. R., Ratovitski, T., van Lare, J., Lee, M. K., Gonzales, V., Jenkins, N. A., Copeland, N. G., Price, D. L., and Sisodia, S. S. 1997. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19:939–945.

    PubMed  Google Scholar 

  7. Holcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., Sanders, S., Zehr, C., O'Campo, K., Hardy, J., Prada, C. M., Eckman, C., Younkin, S., Hsiao, K., and Duff, K. 1998. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4:97–100.

    PubMed  Google Scholar 

  8. Takeuchi, A., Irazarry, M. C., Duff, K., Saido, T. C., Hsaio-Ashe, K., Hasagawa, M., Mann, D., Hyman, B. T., and Iwatsubo, T. 2000. Age-related amyloid β deposition in transgenic mice over-expressing both Alzheimer mutant presenilin 1 and amyloid 3 precursor protein Swedish mutant is not associated with global neuronal loss. Am. J. Pathol. 157:331–339.

    PubMed  Google Scholar 

  9. Chen, G., Chen, K. S., Knox, J., Inglis, J., Bernard, A., Martin, S. J., Justice, A., McConlogue, L., Games, D., Freedman, S. B., and Morris, R. G. 2000. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 408:975–979.

    PubMed  Google Scholar 

  10. Gordon, M. N., King, D. L., Diamond, D. M., Jantzen, P. T., Boyett, K. L., Hope, C. E., Hatcher, J. M., DiCarlo, F., Gottschall, P., Morgan, D., and Arendash, G. W. 2001. Correlation between working memory deficits and Aβ deposits in transgenic APP+PS1 mice. Neurobiol. Aging 22:377–385.

    PubMed  Google Scholar 

  11. Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Liao, Z., Lieberburg, I., Motter, R., Mutter, L., Soriano, F., Shopp, G., Vasquez, N., Vendevert, C., Walker, S., Wogulis, M., Yednock, T., Games, D., and Seubert, P. 1999. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173–177.

    PubMed  Google Scholar 

  12. Bard, F., Cannon, C., Barbour, R., Burke, R. L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Lieberburg, I., Motter, R., Nguyen, M., Soriano, F., Vasquez, N., Weiss, K., Welch, B., Seubert, P., Schenk, D., and Yednock, T. 2000. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6:916–919.

    PubMed  Google Scholar 

  13. Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C., Hardy, J., Duff, K., Jantzen, P., DiCarlo, G., Wilcock, D., Connor, K., Hatcher, J., Hope, C., Gordon, M., and Arendash, G. W. 2000. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408:982–985.

    Google Scholar 

  14. Arendash, G. W., Gordon, M. N., Diamond, D. M., Austin, L. A., Hatcher, J. M., Jantzen, P., DiCarlo, G., Wilcock, D., and Morgan, D. 2001. Behavioral assessment of Alzheimer's transgenic mice following long-term Aβ vaccination: task specificity and correlations between Aβ deposition and spatial memory. DNA Cell Biol. 20:737–744.

    PubMed  Google Scholar 

  15. Weiner, H. L., Lemere, C. A., Maron, R., Spooner, E. T., Grenfell, T. J., Mori, C., Issazadeh, S., Hancock, W. W., and Selkoe, D. J. 2000. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. Neurol. 48:567–579.

    PubMed  Google Scholar 

  16. Lemere, C. A., Maron, R., Spooner, E. T., Grenfell, T. J., Mori, C., Desai, R., Hancock, W. W., Weiner, H. L., and Selkoe, D. J. 2000. Nasal Aβ treatment induces anti-Aβ antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann. N. Y. Acad. Sci. 920:328–331.

    PubMed  Google Scholar 

  17. Lemere, C. A., Spooner, E. T., LaFrancois, J. F., Malester, B., Mori, C., Leverone, J. F., Matsuoka, Y., DeMattos, R. B., Holtzman, D. M., Clements, J. D., Selkoe, D. J., and Duff, K. E. 2002. Evidence for peripheral clearance of Aβ following chronic, active Aβ immunization in PSAPP mice. Neurobiol. Dis. (in press).

  18. Vehmas, A. K., Borchelt, D. R., Price, D. L., McCarthy, D., Wills-Karp, M., Peper, M. J., Rudow, G., Luyinbazi, J., Siew, L. T., and Troncoso, J. C. 2001. β-amyloid peptide vaccination results in marked changes in serum and brain Aβ levels in APP-swe/PS1δE9 mice, as detected by SELDI-TOF-based Protein Chip technology. DNA Cell Biol. 20:713–721.

    PubMed  Google Scholar 

  19. Sigurdsson, E. M., Scholtzova, H., Mehta, P. D., Frangione, B., and Wisniewski, T. 2001. Immunization with a non-toxic/non-fibrillar amyloid-β homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am. J. Pathol. 159:439–447.

    PubMed  Google Scholar 

  20. Das, P., Murphy, M. P., Younkin, L. H., Younkin, S. G., and Golde, T. E. 2001. Reduced effectiveness of Aβ1–42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol. Aging. 22:721–727.

    PubMed  Google Scholar 

  21. Dodart, J.C., Bales, K. R., Gannon, K. S., Greene, S. J., DeMattos, R. B., Mathis, C., DeLong, C. A., Wu, S., Wu, X., Holtzman, D. M., and Paul, S. M. 2002. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat. Neurosci. 5:452–457.

    PubMed  Google Scholar 

  22. Kotilinek, L. A., Bacskai, B., Westerman, M., Kawarabayashi, T., Younkin, L., Hyman, B. T., Younkin, S., and Ashe, K. H. 2002. Reversible memory loss in a transgenic model of Alzheimer's disease. J. Neurosci. 22:6331–6335.

    PubMed  Google Scholar 

  23. Solomon, B., Koppel, R., Hanan, E., and Katzav, T. 1996. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide. Proc. Natl. Acad. Sci. U.S.A. 93:452–455.

    PubMed  Google Scholar 

  24. Solomon, B., Koppel, R., Frenkel, D., and Hanan-Aharon, E. 1997. Disaggregation of Alzheimer β-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. U.S.A. 94:4109–4112.

    PubMed  Google Scholar 

  25. Wilcock, D. M., Gordon, M. N., Ugen, K. E., Gottschall, P. E., DiCarlo, G., Dickey, C., Boyett, K. W., Jantzen, P. T., Connor, K. E., Melachrino, J., Hardy, H., and Morgan, D. 2001. Number of Aβ inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation and congophilic plaque levels. DNA Cell Biol. 20:731–736.

    PubMed  Google Scholar 

  26. Bacskai, B. J., Kajdasz, S. T., Christie, R. H., Carter, C., Games, D., Seubert, P., Schenk, D., and Hyman, B. T. 2001. Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. 7:369–372.

    PubMed  Google Scholar 

  27. Bacskai, B., Kajdasz, S. T., McLellan, M. E., Games, D., Seubert, P., Schenk, D., and Hyman, B. T. 2002. Non-Fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy. J. Neurosci. 22:7873–7878.

    PubMed  Google Scholar 

  28. DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.C., Paul, S. M., and Holtzman, D. M. 2001. Peripheral anti-Aβ antibody alters CND and plasma clearance and decreases brain A3 burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 98:8850–8855.

    PubMed  Google Scholar 

  29. Spooner, E. T., Desai, R., Mori, C., Leverone, J. F., and Lemere, C. A. 2002. The generation and characterization of potentially therapeutic Aβ antibodies in mice: differences according to strain and immunization protocol. Vaccine 21:290–297.

    PubMed  Google Scholar 

  30. Kuper, C. F., Koornstra, P. H., Hameleers, D. M., Biewenga, J., Spit, B. J., Duijvestijn, A. M., van Breda Vriesman, P. J., and Sminia, T. 1992. The role of nasopharyngeal lymphoid tissues. Immunol. Today. 13:219–224.

    PubMed  Google Scholar 

  31. Dickinson, B. L. and Clements, J. D. 1995. Dissociation of Es-cherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immunol. 63:1617–1623.

    Google Scholar 

  32. Del Giudice, G., Pizza, M., and Rappuoli, R. 1999. Mucosal delivery of vaccines. Methods 19:148–155.

    PubMed  Google Scholar 

  33. Cheng, E., Cardenas-Freytag, L., and Clements, J. D. 1999. The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT). Vaccine 18:38–49.

    PubMed  Google Scholar 

  34. Douce, G., Turcotte, C., Cropley, I., Roberts, M., Pizza, M., Domenghini, M., Rappuoli, R., and Dougan, G. 1995. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc. Natl. Acad. Sci. U.S.A. 92:1644–1648.

    PubMed  Google Scholar 

  35. Barackman, J. D., Ott, G., and O'Hagan, T. 1999. Intranasal immunization of mice with influenza vaccine in combination with the adjuvant LT-R72 induces potent mucosal and serum immunity which is stronger than that with traditional intramuscular immunization. Infect. Immunol. 67:4276–4279.

    Google Scholar 

  36. O'Neal, C. M., Clements, J. D., Estes, M. K., and Conner, M. E. 1998. Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge. J. Virol. 72:3390–3393.

    PubMed  Google Scholar 

  37. Cardenas-Freytag, L., Cheng, E., Mayeux, P., Domer, J. E., and Clements, J. D. 1999. Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis. Infect. Immunol. 67:826–833.

    Google Scholar 

  38. Morris, C. B., Cheng, E., Thanawastien, A., and Clements, J. D. 2000. Effectiveness of intranasal immunization with HIV-gp160 Env CTL epitope peptide (E7) in combination with the mucosal adjuvant LT (R192G). Vaccine 18:1944–1951.

    PubMed  Google Scholar 

  39. Gluck, U., Gebbers, J.O., and Gluck, R. 1999. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. J. Virol. 73:7780–7786.

    PubMed  Google Scholar 

  40. Lemere, C. A., Spooner, E. T., Leverone, J. F., Mori, C., and Clements, J. D. 2002. Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants. Neurobiol. Aging 23:991–1000.

    PubMed  Google Scholar 

  41. Town, T., Tan, J., Sansone, N., Obregon, D., Klein, T., and Mullan, M. 2001. Characterization of murine immunoglobulin G antibodies against human amyloid-β1–42. Neurosci. Lett. 307:101–104.

    PubMed  Google Scholar 

  42. Das, P., Minidis, N., and Golde, T. 2002. Effectiveness of Aβ1–42 immunization in the Tg2576 mouse model using DNA vaccination. Neurobiol. Aging. Abstr. 411:S109.

    Google Scholar 

  43. Dickey, C. A., Morgan, D. G., Kudchodkar, S., Weiner, D. B., Bai, Y., Cao, C., Gordon, M. N., and Ugen, K. E. 2001. Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated β-amyloid 1–42 peptide. DNA Cell Biol. 20:723–729.

    PubMed  Google Scholar 

  44. Leverone, J. F., Spooner, E. T., Lehmann, H., Clements, J. D., and Lemere, C. A. 2002. Aβ1–15 is less immunogenic than Aβ1–40/42 for intranasal immunization of wild-type mice but may be effective for boosting. Vaccine. (in press online 23, Dec., 2002).

  45. Schenk, D. 2002. Amyloid-β Immunotherapy for Alzheimer's disease: the end of the beginning. Nature 3:824–828.

    Google Scholar 

  46. Grubeck-Loebenstein, B., Blasko, I., Marx, F., and Trieb, K. 2000. Immunization with β-amyloid: could T-cell activation have a harmful effect? Trends Neurosci. 23:114.

    Google Scholar 

  47. Marx, F., Blasko, I., Pavelka, M., and Grubeck-Loebenstein, B. 1998. The possible role of the immune system in Alzheimer's disease. Exp. Gerontol. 33:871–881.

    PubMed  Google Scholar 

  48. Marx, F., Blasko, I., Zisterer, K., and Grubeck-Loebenstein, B. 1999. Transfected human B cells: a new model to study the functional and immunostimulatory consequences of APP production. Exp. Gerontol. 34:783–795.

    PubMed  Google Scholar 

  49. Newman, M. J., Wu, J.Y., Gardner, B. H., Anderson, C. A., Kensil, C. R., Recchia, J., Coughlin, R. T., and Powell, M. F. 1997. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations. Vaccine 15:1001–1007.

    PubMed  Google Scholar 

  50. Kensil, C. R., Wu, J. Y., Anderson, C. A., Wheeler, D. A., and Amsden, J. 1998. QS-21 and QS-7: purified saponin adjuvants. Dev. Biol. Stand. 92:41–47.

    PubMed  Google Scholar 

  51. Alexander, J., del Guercio, M. F., Maewal, A., Qiao, L., Fikes, J., Chestnut, R. W., Paulson, J., Bundle, D. R., DeFrees, S., and Sette, A. 2002. Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses. J. Immunol. 164:1625–1633.

    Google Scholar 

  52. Bradney, C. P., Sempowski, G. D., Liao, H.X., Haynes, B. F., and Staats, H. F. 2002. Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunizations. J. Virol. 76:517–524.

    PubMed  Google Scholar 

  53. Proietti, E., Bracci, L., Puzelli, S., Di Pucchio, T., Sestili, P., De Vincenzi, E., Venditti, M., Capone, I., Seif, I., De Maeyer, E., Tough, D., Donatelli, I., and Belardelli, F. 2002. Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine models. J. Immunol. 169:375–383.

    PubMed  Google Scholar 

  54. Marinaro, M., Boyaka, P. N., Jackson, R. J., Finkelman, F. D., Kiyono, H., Jirillo, E., and McGhee, J. R. 1999. Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin. J. Immunol. 162:114–121.

    PubMed  Google Scholar 

  55. Kim, S. K., Ragupathi, G., Musselli, C., Choi, S. J., Park, Y. S., and Livingston, P. O. 1999. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines. Vaccine 12:597–603.

    Google Scholar 

  56. Monsonego, A., Zota, V., Selkoe, D., and Weiner, H. 2002. Immunogenic aspects of amyloid-β peptide: Implications for pathogenesis and treatment of Alzheimer's disease. Neurobiol. Aging. Abstr. 503:S133.

    Google Scholar 

  57. Frenkel, D., Katz, O., and Solomon, B. 2000. Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration. Proc. Natl. Acad. Sci. U. S. A. 97:11455–11459.

    PubMed  Google Scholar 

  58. Frenkel, D., Kariv, N., and Solomon, B. 2001. Generation of auto-antibodies towards Alzheimer's disease vaccination. Vaccine 19:2615–2619.

    PubMed  Google Scholar 

  59. Poduslo, J. F. and Curran, G. L. 2001. Amyloid β peptide as a vaccine for Alzheimer's disease involves receptor-mediated transport at the blood-brain barrier. Neuroreport. 12:3197–3200.

    PubMed  Google Scholar 

  60. Munch, G. and Robinson, S. R. 2002. Potential neurotoxic inflammatory responses to Abeta vaccination in humans. J. Neural Transm. 109:1081–1087.

    PubMed  Google Scholar 

  61. Lemere, C. A., Seabrook, T. J., Iglesias, M., Mori, C., Leverone, J. F., and Spooner, E. T. 2002. Modulating amyloid-beta levels by immunotherapy: A potential therapeutic strategy for the prevention and treatment of Alzheimer's disease. In Saido, T. C. (ed), Amyloid-beta Metabolism and Alzheimer's Disease. Landes Bioscience, Georgetown, TX pp. 145–161.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Center for Neurologic Diseases, Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, 02115

    Cynthia A. Lemere, Edward T. Spooner, Jodi F. Leverone, Chica Mori, Melitza Iglesias, Jeanne K. Bloom & Timothy J. Seabrook

Authors
  1. Cynthia A. Lemere
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edward T. Spooner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jodi F. Leverone
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chica Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Melitza Iglesias
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jeanne K. Bloom
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Timothy J. Seabrook
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cynthia A. Lemere.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lemere, C.A., Spooner, E.T., Leverone, J.F. et al. Amyloid-Beta Immunization in Alzheimer's Disease Transgenic Mouse Models and Wildtype Mice. Neurochem Res 28, 1017–1027 (2003). https://doi.org/10.1023/A:1023203122036

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1023203122036

Search

Navigation